Uses of Tavomac DR 40

This is an automatically translated article.

1. What is Tavomac?

Tavomac belongs to the group of gastrointestinal drugs, made in the form of enteric coated tablets and packaged in boxes of 3 blisters x 10 tablets.
Tavomac DR 40 has the main ingredient is Pantoprazol (in the form of Pantoprazol sodium sesquihydrate) 40mg and other excipients.

2. Tavomac drug effects

Tavomac is used in the following cases:
Treatment of gastroesophageal reflux disease. Treatment of peptic ulcers. Prevention of ulcers caused by non-steroidal anti-inflammatory drugs. Zollinger-Ellison syndrome.

3. Dosage - How to take Tavomac

Dosage and administration of Tavomac as follows:
3.1. Dosage Treatment of gastroesophageal reflux syndrome - oesophagitis.
Usual dose: 20-40mg Pantoprazol x 1 time / day for 4 weeks, can last up to 8 weeks. Maintenance dose: 20-40mg Pantoprazol per day. In case of relapse: 20mg Pantoprazol/day. Gastrointestinal ulcers: Usual dose: 40mg Pantoprazol x 1 time/day. The duration of Tavomac treatment is 2-4 weeks for duodenal ulcers or 4-8 weeks for benign gastric ulcers.
Eradicate Helicobacter pylori: Use a 1 week triple combination therapy regimen of 40 mg Pantoprazol x 2 times/day in combination with clarithromycin 500 mg x 2 times/day and amoxicillin 1 g x 2 times/day or metronidazol 400 mg x 2 times/day. day.
Prevention of ulcers caused by non-steroidal anti-inflammatory drugs: Dosage of 20mg Pantoprazol / day.
Zollinger - Ellison syndrome: Initial dose: 80mg Pantoprazol /day. Doses up to 240 mg of pantoprazole/day may be used. If taking more than 80 mg of Pantoprazol/day, it should be divided into 2 times.
Patients with liver failure: Maximum dose: 20mg Pantoprazol / day or 40mg Pantoprazol / day for alternate days.
Patients with renal failure: Maximum dose: 40mg Pantoprazol / day.
3.2. How to take Tavomac is to be taken once a day in the morning. Tavomac tablets should be swallowed whole and not crushed or chewed by the patient.

4. Contraindications to the use of Tavomac

Tavomac is contraindicated in patients with known hypersensitivity to pantoprazole or to any of the ingredients or to other benzimidazole derivatives such as esomeprazole, omeprazole, lansoprazole and abeprazole.

5. Tavomac drug interactions

The following are some of the reported drug interactions of Tavomac such as:
Drugs with gastric pH dependent absorption such as ketoconazole, ampicillin ester, iron salts when concomitantly administered with pantoprazole may increase or decrease absorption. of the drug when increasing the pH of the stomach. Pantoprazole has been reported to be extensively metabolized in the liver, primarily by cytochrome P450 (CYP) isoenzyme 2C19, to a lesser extent by isoenzymes CYP3A4, CYP2C9 and CYP2D6. However, clinical trials revealed no clinically important interactions between other drugs metabolized by the same isoenzyme and pantoprazole. Warfarin in combination with Tavomac has the potential to increase INR and prothrombin time. Given the increased risk of abnormal bleeding and death, patients should be monitored for elevations in INR and prothrombin time when Tavomac is co-administered with warfarin. There are data to suggest that sucralfate may reduce the bioavailability and slow absorption of proton pump inhibitors such as omeprazole and lansoprazole, so a proton pump inhibitor should be taken at least 30 minutes before taking sucralfate.

6. What side effects does Tavomac cause?

In general, Tavomac is well tolerated even with short-term and long-term treatment. However, during use with Tavomac, patients may experience some unwanted side effects such as:
Common
Fatigue, headache. Skin rash, hives. Muscle pain, joint pain. Uncommon
Asthenia, fatigue, dizziness, lightheadedness. Itchy. Increase liver enzymes. Rare
Anaphylaxis, diaphoresis, peripheral edema, malaise. Macular rash, exfoliative dermatitis, acne, alopecia, angioedema, erythema multiforme. Stomatitis, gastrointestinal disturbances, belching/ belching. Blurry vision, photophobia. Insomnia, somnolence, tinnitus, paresthesia, agitation or inhibition, tremor, confusion, hallucinations. Eosinophilia, agranulocytosis, thrombocytopenia and leukopenia. Impotence. Hematuria, interstitial nephritis. Hepatitis, increased triglycerides, jaundice, encephalopathy in people with liver failure. Decreased blood sodium.

7. Pay attention to the drug Tavomac

Precautions when using Tavomac in the following cases:
Long-term treatment with Tavomac and high doses and long-term use (> 1 year), may slightly increase the risk of wrist and vertebrae, hip fractures, which mainly occur in the elderly or those with other risk factors. Proton pump inhibitors have been reported to increase the risk of fracture by 10 to 40%. Patients at risk of osteoporosis must be closely cared for and need adequate vitamin D and calcium supplements. Severe hypomagnesaemia has been reported in patients treated with proton pump inhibitors for at least 3 months and usually for about 1 year. Symptoms of severe hypomagnesaemia may occur, such as delirium, convulsions, fatigue, muscle spasticity, dizziness, and ventricular arrhythmias, but these symptoms may be insidious and go unnoticed. . In the majority of patients with hypomagnesaemia, the condition improved after magnesium supplementation and discontinuation of proton pump inhibitors. It is advisable to measure magnesium levels before initiating therapy with Tavomac and periodically during treatment in patients requiring long-term therapy or requiring concomitant proton pump inhibitors and hypomagnesaemic agents or digoxin. . Symptomatic response to treatment with Tavomac did not prevent gastric tumor progression. The possibility that a malignant peptic ulcer should be excluded prior to administration of Tavomac may mask symptoms and thereby delay diagnosis. Transient elevations in serum ALT (SGPT) have been reported during treatment with oral pantoprazole. Malabsorption of cyanocobalamin. Decreased gastric acidity or gastric acidosis due to long-term (more than 3 years) daily treatment of acid-suppressing drugs may reduce the absorption of cyanocobalamin. The safety and effectiveness of Tavomac in children under 18 years of age have not been established. There are no adequate and well-controlled studies of Tavomac DR 40 in pregnant women. Women who are pregnant should not take Tavomac DR 40 unless absolutely necessary. Tavomac DR 40 is distributed into breast milk, therefore nursing or Tavomac DR 40 should be discontinued due to potential risks to the nursing infant. Tavomac DR 40 may cause side effects such as dizziness and visual disturbances. If these side effects occur, the patient should not drive or operate machinery. Tavomac drug with main ingredient is Pantoprazol, used in the treatment of gastroesophageal reflux disease, gastrointestinal ulcers, ulcer prevention due to non-steroidal anti-inflammatory drugs, Zollinger-Ellison syndrome,... To ensure the effectiveness of treatment and avoid unwanted side effects, patients need to strictly follow the instructions of the doctor, professional pharmacist.
Follow Vinmec International General Hospital website to get more health, nutrition and beauty information to protect the health of yourself and your loved ones in your family.

Please dial HOTLINE for more information or register for an appointment HERE. Download MyVinmec app to make appointments faster and to manage your bookings easily.